# Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

> **NCT03145012** · PHASE4 · COMPLETED · sponsor: **Nova Scotia Health Authority** · enrollment: 30 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Ranitidine

## Key facts

- **NCT ID:** NCT03145012
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-10-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145012, "Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03145012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*